Woodline Partners’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
Other funds holding COGT
Woodline Partners's COGT Position: Q3 2026 in Review
Woodline Partners reduced its Cogent Biosciences (COGT) stake by 23% in Q3 2026, selling an estimated $22.3M and leaving 2,000,498 shares worth $64.1M. The position accounts for 0.19% of the portfolio, ranked #118.
Woodline Partners first reported a position in COGT in Q1 2022 and has held it in 15 quarters since. The position peaked at $101M in Q2 2026. 208 funds tracked by Wall St. Rank hold COGT as of Q3 2026.
- Woodline Partners held 2,000,498 shares of Cogent Biosciences worth $64.1M as of Q3 2026.
- Woodline Partners sold 602,664 Cogent Biosciences shares in Q3 2026, an estimated $22.3M.
- Cogent Biosciences made up 0.19% of Woodline Partners's portfolio in Q3 2026, its #118 holding.
- Woodline Partners first reported a position in Cogent Biosciences in Q1 2022 and has held it in 15 quarters since.
- Woodline Partners's Cogent Biosciences position peaked at $101M in Q2 2026.
- 208 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.